BioPharmSignal logoBioPharmSignal

Biotech News

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept (CORT)CorceptCommercial

REDWOOD CITY, Calif. --(BUSINESS WIRE)--May 27, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

Open original release

Related news

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

CORTCorcept2026-02-19 21:00 EST

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

CRNXCrinetics Pharmaceuticals2026-06-02 20:05 EST

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

NBIXNeurocrine Biosciences2026-05-06 12:30 EST

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

CRNXCrinetics Pharmaceuticals2026-04-27 21:13 EST

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

AMPHAmphastar Pharmaceuticals, Inc.2020-10-06 10:00 EST

Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection

View all latest news

Corcept

Corcept Therapeutics is a biotechnology company focused on cortisol modulation and endocrine disease, with a commercial franchise in Cushing’s syndrome and additional pipeline opportunities. Its business combines specialty commercialization with clinical development.

Recent company news

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

CORTCorcept2026-05-27 12:00 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-04-30 20:05 EST

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

CORTCorcept2026-04-30 20:05 EST

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-04-23 20:05 EST

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Stock data

Close
91.12 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States